26
August
2009

Obesity And Weight Management Explores Link Between Erectile Dysfunction And Obesity0

Obese men are at increased risk for erectile dysfunction (ED), likely caused by atherosclerosis-related hypertension and cardiovascular disease, as well as hormonal changes associated with obesity, as described in a timely article published in Obesity and Weight Management, a journalzine published by Mary Ann Liebert, Inc. The article is available free online at http://www.liebertpub.

Posted: Medical News

25
August
2009

Link Between Erectile Dysfunction And Obesity Explored In Obesity And Weight Management0

Obese men are at increased risk for erectile dysfunction, likely caused by atherosclerosis-related hypertension and cardiovascular disease, as well as hormonal changes associated with obesity.

Posted: Medical News

14
August
2009

Palatin Technologies, Inc. Reports Positive Bremelanotide Study; Improved Safety Profile With Subcutaneous Administration0

Palatin Technologies, Inc. (NYSE Amex: PTN) announced the completion of a Phase 1 clinical trial of subcutaneously administered bremelanotide, its melanocortin agonist drug candidate for treatment of male erectile dysfunction (ED) and female sexual dysfunction (FSD). The results demonstrate that with subcutaneous administration consistent therapeutic blood plasma levels can be obtained without blood pressure side effects.

Posted: Medical News

10
August
2009

Erectile Aid Use By Men Treated For Localized Prostate Cancer0

UroToday.com – A UCLA single-institution study in the online edition of the Journal of Urology reports on the use of erectile aid (EA) following treatment for localized prostate cancer (CaP). Participants with a diagnosis of CaP were prospectively recruited between 1999 and 2003. Clinical and pathological data was abstracted and HRQOL (Health Related Quality of Life) outcomes were prospectively abstracted at baseline and 1, 2, 4, 8, 12, 18, 24, 30, 36, 42 and 48 months.

Posted: Medical News

4
August
2009

Oncological Results, Functional Outcomes, Quality-of-Life – Radical Prostatectomy Or External Beam Radiation Therapy For Localized Prostate Cancer0

UroToday.com – Most recently, health-related quality-of-life (HRQOL) after definitive local therapy for prostate cancer has been argued in the patient group with an oncological risk category.

Posted: Medical News

1
August
2009

Sciele Pharma And Plethora Solutions Announce Positive Results Of Final Phase III Pivotal Trial For PSD502 For Premature Ejaculation0

Sciele Pharma Inc., a Shionogi Company, and Plethora Solutions Holdings PLC (”Plethora” – AIM:PLE), announced that a second and final Phase III double-blind, placebo-controlled study of PSD502 for the treatment of premature ejaculation (’PE’) has met all co-primary endpoints of Intra-vaginal Ejaculation Latency Time (’IELT’), Index of Premature Ejaculation (’IPE,’ Ejaculatory Control, Sexual Satisfaction and Distress domains).

Posted: Medical News